MDS 2023 | Pre-MDS states: identifying patients at risk and using modern tools to improve prognosis
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, discusses approaches to identify patients with pre-myelodysplastic syndromes (MDS) states. Prof. Mittelman explains that it is important to identify patients at risk, as early intervention may prevent progression to MDS and ultimately transformation to acute myeloid leukemia (AML). Prof. Mittelman further discusses recent advances in genetic techniques and the implementation of AI to improve prediction, classification, treatment, and outcomes for patients with MDS. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Research Funding; Takeda: Honoraria, Research Funding; Janssen: Research Funding; Roche: Research Funding; BMS: Research Funding; Celgene: Research Funding; Medison: Research Funding; Gilead: Research Funding.
